CSA Medical closed $53M Series D round

CSA Medical Inc. completed an oversubscribed $53 million Series D preferred stock equity financing. The funding round was co-led by TVM Capital Life Science and Yonjin Ventures, with participation from existing shareholders SV Health Investors, Ascension Ventures, First Analysis, Blue Heron, and Intersouth Partners.

The company is developing the RejuvenAir® System, a medical device that uses liquid nitrogen spray cryotherapy for the treatment of chronic bronchitis, a subset of Chronic Obstructive Pulmonary Disease (COPD). The funds are intended to support the company through the U.S. Food and Drug Administration (FDA) premarket approval (PMA) process and to build a comprehensive commercialization strategy for a successful U.S. launch of the RejuvenAir System. The RejuvenAir System is designed to target and destroy damaged cells in the airways without creating scar tissue, allowing for the regrowth of healthy cells.